Celon Pharma S.A. (WSE:CLN)
Poland · Delayed Price · Currency is PLN 20.50
-0.40 (-1.91%)
Jun 16, 2026, 3:00 PM CET
Celon Pharma Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Celon Pharma stock has a consensus rating of "Hold" and an average price target of zł 20.44. The average 1-year stock price forecast is 0.29% lower than the current stock price, while the lowest is zł 16.00 (-21.95%) and the highest is zł 25.50 (+24.39%).
Price Target: zł 20.44 (-0.29%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Celon Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 2 | 2 | 2 | 2 | 2 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Financial Forecast
Revenue This Year
234.50M
from 205.55M
Increased by 14.09%
Revenue Next Year
290.50M
from 234.50M
Increased by 23.88%
EPS This Year
-1.34
from -0.66
EPS Next Year
-0.44
from -1.34
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is PLN.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 236.8M | ||
| Avg | 234.5M | ||
| Low | 232.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 15.2% | ||
| Avg | 14.1% | ||
| Low | 12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.34 | ||
| Avg | -1.34 | ||
| Low | -1.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |